Bridgeway Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Bridgeway Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23,700	Closed	-$181K	–	1381
2020 Q2	$181K	Sell	23,700 -30,100	-56%	-$230K	﹤0.01%	1167
2020 Q1	$332K	Sell	53,800 -150,000	-74%	-$1.32M	0.01%	894
2019 Q4	$2.48M	Sell	203,800 -6,100	-3%	-$66.7K	0.03%	448
2019 Q3	$2.42M	Hold	209,900	–	–	0.03%	431
2019 Q2	$2.1M	Sell	209,900 -50,000	-19%	-$539K	0.03%	510
2019 Q1	$3.35M	Buy	259,900 +97,900	+60%	+$1.46M	0.04%	347
2018 Q4	$2.46M	Buy	162,000 +30,100	+23%	+$574K	0.03%	421
2018 Q3	$2.64M	Buy	131,900 +85,000	+181%	+$1.94M	0.03%	538
2018 Q2	$915K	Hold	46,900	–	–	0.01%	904
2018 Q1	$945K	Hold	46,900	–	–	0.01%	866
2017 Q4	$621K	Sell	46,900 -28,600	-38%	-$431K	0.01%	1023
2017 Q3	$1.39M	Hold	75,500	–	–	0.02%	718
2017 Q2	$1.39M	Buy	75,500 +14,500	+24%	+$287K	0.02%	714
2017 Q1	$1.38M	Buy	61,000 +25,000	+69%	+$599K	0.02%	699
2016 Q4	$1.25M	Hold	36,000	–	–	0.02%	725
2016 Q3	$882K	Hold	36,000	–	–	0.01%	851
2016 Q2	$861K	Hold	36,000	–	–	0.01%	837
2016 Q1	$842K	Hold	36,000	–	–	0.01%	836
2015 Q4	$1.09M	Buy	+36,000	New	+$1.16M	0.02%	720

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bridgeway Capital Management's AMAG Position: Q3 2020 in Review

Bridgeway Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2020, closing a stake of 23,700 shares — an estimated $181K sold.

Bridgeway Capital Management first reported a position in AMAG in Q4 2015 and held it in 19 quarters. The position peaked at $3.35M in Q1 2019. 113 funds tracked by Wall St. Rank hold AMAG as of Q3 2020.

Bridgeway Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bridgeway Capital Management sold 23,700 AMAG Pharmaceuticals shares in Q3 2020, an estimated $181K.
Bridgeway Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 19 quarters.
Bridgeway Capital Management's AMAG Pharmaceuticals position peaked at $3.35M in Q1 2019.
113 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2020.

Based on Bridgeway Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.